Maggiolo F - Search Results

1

One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.

Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, Gori A, Suter F, Maggiolo F. Airoldi M, et al. Among authors: maggiolo f. Patient Prefer Adherence. 2010 May 13;4:115-25. doi: 10.2147/ppa.s10330. Patient Prefer Adherence. 2010. PMID: 20517472 Free PMC article.

2

Teicoplanin versus cefamandole in the prevention of infection in total hip replacement.

Suter F, Avai A, Fusco U, Gerundini M, Caprioli S, Maggiolo F. Suter F, et al. Among authors: maggiolo f. Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):793-6. doi: 10.1007/BF02111338. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7889947 Clinical Trial.

3

Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: preliminary clinical experience.

Maggiolo F, Taras A, Pravettoni MG, Leone M, Ingrosso A, Suter F. Maggiolo F, et al. Infection. 1997 Jan-Feb;25(1):35-8. doi: 10.1007/BF02113505. Infection. 1997. PMID: 9039536 Clinical Trial.

4

Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model.

Maggiolo F, Capra R, Bartoli A, Bottura P, Migliorino M, Suter F. Maggiolo F, et al. J Chemother. 2000 Apr;12(2):129-33. doi: 10.1179/joc.2000.12.2.129. J Chemother. 2000. PMID: 10789551

5

Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.

Paolucci S, Baldanti F, Maserati R, Castelli F, Suter F, Maggiolo F, Pan A, Gerna G. Paolucci S, et al. Among authors: maggiolo f. Antiviral Res. 2000 Feb;45(2):101-14. doi: 10.1016/s0166-3542(00)00062-0. Antiviral Res. 2000. PMID: 10809019

6

In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.

Maggiolo F, Capra R, Bottura P, Pravettoni G, Migliorino M, Suter F. Maggiolo F, et al. J Chemother. 2000 Jun;12(3):195-8. doi: 10.1179/joc.2000.12.3.195. J Chemother. 2000. PMID: 10877512

7

Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment.

Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Maggiolo F, et al. J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):36-43. doi: 10.1097/00042560-200009010-00005. J Acquir Immune Defic Syndr. 2000. PMID: 11064502 Clinical Trial.

8

Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.

Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Arici C, et al. Among authors: maggiolo f. Int J STD AIDS. 2001 Jun;12(6):407-9. doi: 10.1258/0956462011923228. Int J STD AIDS. 2001. PMID: 11368826

9

Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.

Arici C, Ripamonti D, Ravasio V, Maggiolo F, Rizzi M, Finazzi MG, Suter F. Arici C, et al. Among authors: maggiolo f. Int J STD AIDS. 2001 Sep;12(9):573-81. doi: 10.1258/0956462011923741. Int J STD AIDS. 2001. PMID: 11516366

10

Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.

Carosi G, Castelli F, Suter F, Maggiolo F, Orani AM, Pan A, Andreoni M, Vigevani GM, Maserati R, Mazzotta F, Tinelli C; MATER Study Group. Carosi G, et al. Among authors: maggiolo f. HIV Clin Trials. 2001 Sep-Oct;2(5):399-407. doi: 10.1310/5xcl-5xe9-jafk-xk7y. HIV Clin Trials. 2001. PMID: 11673814 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters